Diagnostics
ONCOLOGY
The unique capacity of NBI to isolate intact and polydisperse vesicles enables the development of new approaches to detect early cancer or Minimal Residual Disease (MRD) biomarkers based on combinations of several markers.
Electron Microscopy image of particles isolated by NBI showing intact and polydisperse vesicles.
Besides, we have applied blood microdissection to discover a novel biomarker with a potential to screen colorectal cancer (CRC) and Non Small Cell Lung Cancer (NSCLC).
EVBiome biomarker tested (and replicated) on 15 early stage (I or II) CRC patients (left) and 18 early stage NSCLC patients (right), compared with 30 healthy controls.
At this stage, the performance of our proprietary colorectal cancer screening test is comparable to that of the fecal immunochemical test (FIT):
Performance of EVBiome biomarker vs. FIT
| Specificity | Sensitivity (stage I-II) | Assay type | |
|---|---|---|---|
| FIT* | 94.8% | 66-76% | Fecal |
| EVBiome | 94.4% | 73.3% | Blood |
Thanks to our low cost of goods (COGs), we believe this solution has the potential to make a global impact by increasing access to screening and ultimately reducing colorectal cancer mortality worldwide.
NEURODEGENERATIVE DISEASES and INFECTIOUS DISEASES
Beyond oncology, we are actively advancing our biomarker discovery efforts in areas of high unmet medical need, including neurodegenerative diseases such as Parkinson’s disease, and infectious diseases like Lyme disease and chronic tuberculosis. Our goal remains consistent: to develop accessible, high-impact diagnostic tools that can transform patient outcomes and contribute to improving global health at scale.